












1334Unrelated Donor Hematopoietic Cell Transplantation:
Factors Associated with a Better HLA Match
Jason Dehn,1 Mukta Arora,2 Stephen Spellman,1 Michelle Setterholm,1 Mary Horowitz,3
Dennis Confer,1 Daniel Weisdorf 2The impact of non-HLA patient factors on the match of the selected unrelated donor (URD) for hematopoi-
etic cell transplantation (HCT) has not been fully evaluated. National Marrow Donor Program (NMDP) data
for 7486 transplants using peripheral blood stem cells (PBSCs) or bone marrow from years 2000 to 2005
were evaluated using multivariate logistic regression to identify independent non-HLA patient factors asso-
ciated with completing a more closely matched URD transplant. Advanced (intermediate- and late-stage) dis-
ease was significantly associated with an increased likelihood of transplant using a less-matched (partially
matched or mismatched) donor. Additionally, Black patients were 2.83 times, Asian patients 2.05 times,
and Hispanic patients 1.73 times more likely to have a less-matched HCT donor than Caucasian patients.
Younger patients, HCTat lower volume centers, and in earlier years had significantly higher likelihood of hav-
ing a less HLA matched URD transplant. Our analysis provides encouraging evidence of HLA matching im-
provement in recent years. Initiating a patient’s URD search early in the disease process, especially for
patients from non-Caucasian racial and ethnic groups, will provide the best likelihood for identifying the
best available donor and making informed transplant decisions.
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Allogeneic hematopoietic cell transplantation
(HCT) is a potentially curative therapy for malignant
and nonmalignant hematologic disorders. Unfortu-
nately, only 30% of patients in need of HCT will
have a suitable human leukocyte antigen (HLA)
matched family member. For the remainder of pa-
tients, searching for an unrelated donor (URD) is an
important option. The National Marrow Donor Pro-
gram (NMDP) is the largest URD registry in the
world, and has facilitated donor searches and more
than 30,000 transplants since 1987.
Previous studies have assessed the impact of HLA
matching on patient outcomes such as graft failure,1National Marrow Donor Program, Minneapolis, Minne-
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6/j.bbmt.2008.09.009overall survival (OS), disease-free survival (DFS), and
graft-versus-host disease (GVHD). Studies have
shown varying levels of how HLA mismatching has
an impact survival [1-4]. Recent work by Lee et al.
has shown important adverse effects of either allele
or antigen mismatching on outcome with 9% to
10% lower 1-year survival for each additional mis-
match (7 of 8 and 6 of 8 HLA-A, -B, -C, -DRB1) com-
pared to fully matched (8 of 8) transplants [5]. Studies
have demonstrated the need for high-resolution 4 locus
typingHLA-A, -B, -C, and -DRB1 [3-7]. The 3 largest
studies from Morishima et al. [3], Lee et al. [5] and
Flomenberg et al. [6]. showed no significant differ-
ences in patient outcome associated with mismatching
at HLA-DQB1.
The impact of non-HLA patient factors on the se-
lection of anURD for proceeding to transplant has not
been fully evaluated. Understanding how patient fac-
tors may impact donor selection, availability, and com-
pletion of a transplant is important given the influence
of donormatching on survival. TheNMDPRegistry is
underrepresented in available donors from non-Cau-
casian racial and ethnic groups. As of 2005, approxi-
mately 72% of the donor file was composed of
Caucasian donors.
We analyzed the trend of patient/donor pairs
undergoing transplant in the 6-year period of
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donor searching and availability of better matched do-
nors. With HLA match level as an important compo-
nent of favorable transplant outcome, we evaluated
the factors associated with HCT using a better
matched donor.PATIENTS AND METHODS
Patient Population
This observational study includes patients receiving
their first transplant facilitated through the NMDP
from years 2000 to 2005. Patient and donor pairs con-
sented to having their data used for research, and were
included if baseline information was available (n 5
7486; 78% of domestic and 17% of international
NMDPtransplants). Patientswere transplantedwith ei-
ther peripheral blood stem cells (PBSC) or bone mar-
row. The patient data, 94.5% in the United States and
5.5% international patients, come from 168 transplant
centers. This cohort of patients is 82% Caucasian, 6%
Black, 2%Asian, 8%Hispanic, and2%other/unknown.
Patient race designation was based on transplant center
reporting. Hispanic patients include those specified as
Hispanic race or those of Hispanic ethnicity with Cau-
casian or other/unknown race selected. Patient age in-
cludes 25% of patients 19 years or under, 46% age 20
to 49 years, and 28% age 50 years or older.
HLATyping
HLA data used in this study were the NMDP best
available HLA typings. Typing data includes 42% up-
dated by HLA-A, -B, -C, -DRB1 high-resolution typ-
ing performed through the NMDP Donor-Recipient
Pair project [6,8], with the remaining 58% at various
levels of resolution and number of loci tested submit-
ted to the NMDP by the transplant center.
HLA Matching
HLA typing was evaluated for allele and antigen
level mismatches across 4 loci HLA-A, -B, -C, and
-DRB1. HLA-DQ was excluded because of a limited
effect on outcome, and HLA-DP was excluded based
on low rates of the transplant center HLA-DP typing
practices, low frequency of unrelated matching, and
conflicting estimates of its impact [5,6,8,9]. The co-
hort data were categorized into 3 HLA match levels,
to evaluate HLA typing between patient and donor
that included variation in resolution and number of
loci typed (e.g., missing HLA-C), based on an analysis
performed by NMDP/Center for International Blood
and Marrow Transplant Research (CIBMTR) using
survival outcomes data [10].
Using this method to categorize the patient/donor
matching, match outcome was categorized as ‘‘well-matched’’ (zero or likely no mismatches present) n 5
4329 (58%), ‘‘partiallymatched’’ (1 or likely 1mismatch
present) n 5 2192 (29%), and ‘‘mismatched’’ ($2 or
likely 2 or more mismatches present) n 5 965 (13%).Statistical Methods and Definitions
Descriptive analysis was performed using fre-
quency and univariate analysis across HLA match cat-
egories using chi-square (categoric) or Kruskal-Wallis
(continuous) tests. Ordered regression on the 3 levels
of matching failed the proportional odds assumption
of the cumulative logit model, so continuation ratio
modeling was used to describe the odds ratios (OR)
and 95% confidence intervals (CI) [11,12]. Binary lo-
gistic regression was performed to test well-matched
pairs versus partially matched plus mismatched pairs
(combination referred to as ‘‘less-matched’’). A subse-
quent logistic regression comparing only the partially
matched versus mismatched pairs (n 5 3138) was
performed.
Logistic regression was performed using SAS
statistical software version 9.1 (SAS Institute Inc.,
Cary, NC) with match category as the dependent vari-
able and independent variables being patient age, dis-
ease/stage at transplant, race, sex, transplant year,
transplant center volume, transplant center location
(international or domestic), NMDP formal search to
transplant time, race matched donor status, graft
source (PBSC or bone marrow), cytomegalovirus
(CMV) serostatus of patient and donor, and condition-
ing intensity. Patient age was categorized into 3 dis-
crete groups (#19, 20-49, and 501years) because of
nonlinear effects. Disease was categorized by broad
disease and underlying stage if applicable. Disease cat-
egories included acute myelogenous leukemia (AML),
acute lymphoblastic leukemia (ALL), chronic myelog-
enous leukemia (CML), myelodyplastic syndrome
(MDS), lymphoma (includes Hodgkin and non-Hodg-
kin), other leukemias, other malignant disease, other
nonmalignant disease
(includes histiocytosis and inherited blood and meta-
bolic disorders), and severe aplastic anemia (SAA).
Disease stage at transplant was categorized, as
follows, for AML, ALL, CML, andMDS. For patients
with AML and ALL, early stage was defined as first
complete remission, intermediate stage as second
complete remission or greater, and late stage as relapse
or primary induction failure. Early stage in CML was
defined as first chronic phase, intermediate stage in-
cluded second chronic phase or greater and accelerated
phase, and late stage included patients with blast crisis.
Early stage disease in MDS was defined as refractory
anemia and refractory anemia with ringed sideroblasts,
and late stage as refractory anemia with excess blasts,
refractory anemia with excess blasts in transformation,
and chronic myelomonocytic leukemia.









Median age in years (range) 7486 41.3 (0.13-78.1) 36.6 (0.36-74.9) 28.2 (0.38-79.3) <.0001
Male gender 7486 59% 58% 60% 0.78
Search to transplant median days (range) 7485 101 (15-4110) 116 (17-5102) 128 (29-2744) <.0001
Donor
Median age in years (range) 7480 34.7 (18.6-61.1) 35.7 (19.0-60.8) 36.1 (18.6-60.4) <.0001
Gender
Male 7486 67% 59% 56% <.0001
Female
0 pregnancy 14% 15% 14%
$1 pregnancy 18% 24% 28%
Unknown pregnancy 2% 2% 2%
Graft
Bone marrow graft 7486 49% 56% 65% <.0001
Race matched % 7378 88% 81% 69% <.0001
Reduced intensity conditioning 7478 32% 28% 24% <.0001
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in 2-year intervals. Transplant center volume was cat-
egorized into 3 levels based on the centers average
NMDP transplants per year, over the 6 years repre-
sented in this study: low volume (\10 per year) n 5
132; medium volume (10-25) n 5 25; high volume
(261) n 5 11. NMDP formal search to transplant
time, defined as the number of days between the date
of first requested donor activity and date of transplant,
was categorized into 4 groups (#60, 61-120, 121-180,
1811years) because of nonlinear effects.Figure 1. HLA match category across racial/ethnic groups.RESULTS
Patient and Transplant Characteristics
The patient, donor, and graft characteristics strat-
ified by HLA match category (Table 1) shows a signif-
icantly older median patient age between patients
transplanted with a well-matched donor (median 41
years) compared with a mismatched donor (28 years).
Search time also differs, with a median time that was
2 weeks longer for a partially matched transplant and
almost 4 weeks longer for a mismatched transplant,
compared to the well-matched group. Patients with
less-matched donors had a significantly greater pro-
portion of female donors, particularly with prior preg-
nancies, than well-matched HCT recipients.
The distribution of donor HLA match across pa-
tient racial groups showCaucasian patients were trans-
planted mostly with well-matched donors (62%),
while patients of non-Caucasian racial groups had
a higher percentage of both partially and mismatched
donor transplants (Figure 1). Univariate analysis of pa-
tient age and HLA match levels showed that older pa-
tients were less commonly transplanted with
mismatched donors (Figure 2).
Encouragingly, over the years of study, a progres-
sive increase in well-matched donors and decrease in
partially matched and mismatched donors was ob-served (Figure 3). This overall increase in transplants
using well-matched donors was similar across all racial
groups. The largest percentage decline in use of mis-
matched donors from 2000/2001-2004/2005 occurred
in patients from non-Caucasian racial groups; Black
(222%), Asian (219%), Hispanic (224%) versus
Caucasian (213%).
For AML and CML, intermediate- and late-stage
disease was associated with a somewhat higher propor-
tion of HCT using a partially matched or mismatched
donor (Table 2). ALL and MDS showed a similar pat-
tern, but to a lesser extent.Multivariate Analysis
Multivariate logistic regression analysis was per-
formed to analyze the factors associated with having
a transplant using a donor from the 3 HLA match
levels (Table 3). The effect of race on HLA matching
was pronounced. Black patients were 2.83 times, Asian
2.05 times, and Hispanic 1.73 times more likely to
Figure 2. HLA match category across patient age groups.
Table 2. Disease/Stage: HLA Match Category
Disease—Stage Well Matched Partially Matched Mismatched
Total* 4319 (58%) 2183 (29%) 958 (13%)
AML
Early 553 (67%) 199 (24%) 75 (9%)
Intermediate 379 (53%) 236 (33%) 97 (14%)
Late 501 (56%) 275 (31%) 122 (14%)
ALL
Early 253 (55%) 150 (33%) 54 (12%)
Intermediate 340 (51%) 209 (32%) 114 (17%)
Late 164 (54%) 86 (28%) 55 (18%)
CML
Early 313 (59%) 151 (29%) 63 (12%)
Intermediate 162 (50%) 115 (36%) 46 (14%)
Late 31 (43%) 27 (38%) 14 (19%)
MDS
Early 118 (67%) 41 (23%) 16 (9%)
Late 263 (62%) 123 (29%) 40 (9%)
Unknown 91 (65%) 37 (26%) 12 (9%)
Lymphoma 410 (64%) 175 (27%) 53 (8%)
Other leukemia 259 (65%) 92 (23%) 49 (12%)
Other malignancy 156 (63%) 63 (26%) 27 (11%)
Nonmalignancy 154 (50%) 91 (30%) 60 (20%)
SAA 172 (50%) 113 (33%) 61 (18%)
AML indicates acute myelogenous leukemia; ALL, acute lymphoblastic
leukemia; CML, chronic myelogenous leukemia; MDS, myelodysplastic
syndrome; SAA, severe aplastic anemia. Nonmalignant diseases include
immunodeficiencies, inborn errors of metabolism, hemoglobinopathies.
*Twenty-six patients missing disease stage: AML5 14, ALL5 9, CML5 3.
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donor than Caucasian patients. This effect was also
shown when comparing the less-matched donors be-
tween the partially matched and mismatched groups.
Older patient age was associated with significantly
greater likelihood of having a well-matched donor se-
lected. Patients age 50 and over were significantly less
likely to have a less-matched donor (OR 5 0.73, 95%
CI 0.62-0.85, P\ .0001), compared to patients under
the age of 20 years. Patient age was also analyzed by de-
cade (data not shown) and the findings were concor-
dant with the 3 discrete age groups shown.
Advanced disease was associated with increased
likelihood of transplant with a donor mismatch.
AML-intermediate stage was 1.55 times more likelyFigure 3. HLA match category by year.(95% CI 1.25-1.93, P\ .0001) and AML-late stage
1.50 times more likely (95% CI 1.23-1.85, P \
.0001) to have a less-matched HCT than AML-early
stage. Similarly, intermediate- and late-stage CML
was associated with less-matched donors, OR 5 1.84
(95% CI 1.36-2.48, P\ .0001) and OR 5 2.35 (95%
CI 1.38-4.02, P 5 .0017) compared to early-stage
CML, respectively. Similar associations were noted
for late stage MDS OR 5 1.48 (95% CI 1.00-2.19, P
5 .052), but not for the other malignant or the nonma-
lignant diseases.
Other factors beyond patient demographics includ-
ing transplant center, year of transplant, and search time
to transplant also showed an association with the HLA
match outcome. Transplant centers with the lowest
volume of transplants were more likely than high
volume centers to select a less-matched donor, OR 5
1.20 (95% CI 1.07-1.36, P 5 .003). There were also
increased odds of less-matched transplants from inter-
national transplant centers.
Encouragingly, mismatches were less frequent in
more recent years. HCT in 2000/2001 were 2.47 times
(95% CI 2.18-2.79, P\ .0001) more likely to be less-
matched compared to years 2004/2005. Transplants
between pairs not racially matched were 1.6 times
more likely to be less-matched. Neither graft source,
conditioning intensity, nor patient and donor CMV
serostatus were significantly associated with matching
category (data not shown), and, therefore, were not
included in the final model.
Table 3. Factors Associated with a Less-Matched Transplant: Multivariate Analysis*
Partially/Mismatched versus Well-Matched (ref) (N 5 7449) Mismatched versus Partially Matched (ref) (N 5 3138)
Variable OR 95% CI P-Value OR 95% CI P-Value
Age
0-19 (ref) 1.00 — .0004 1.00 — .0087
20-49 0.86 0.75-0.98 0.75 0.61-0.92
50+ 0.73 0.62-0.85 0.70 0.54-0.91
Sex
Male (ref) 1.00 — .94 1.00 — .42
Female 1.00 0.90-1.10 0.94 0.80-1.10
Race
Caucasian (ref) 1.00 — <.0001 1.00 — <.0001
Black 2.83 2.26-3.54 1.85 1.41-2.44
Asian 2.05 1.47-2.85 2.14 1.42-3.22
Hispanic 1.73 1.41-2.12 1.87 1.42-2.45
Other/Unknown 1.56 0.94-2.56 2.17 1.10-4.27
Race matched with donor
Yes (ref) 1.00 — <.0001 1.00 — .0004
No 1.60 1.37-1.86 1.45 1.17-1.79
Unknown 1.12 0.66-1.91 0.52 0.20-1.34
Disease
AML— Early† 1.00 — <.0001 1.00 — .15
Intermediate 1.55 1.25-1.93 1.00 0.69-1.45
Late 1.50 1.23-1.85 1.17 0.82-1.67
ALL—Early† 1.00 — 1.00 –
Intermediate 0.95 0.74-1.23 1.26 0.84-1.89
Late 0.90 0.66-1.22 1.74 1.08-2.81
CML—Early† 1.00 — 1.00 —
Inter. 1.84 1.36-2.48 1.18 0.73-1.89
Late 2.35 1.38-4.02 1.44 0.68-3.04
MDS—Early† 1.00 — 1.00 —
Late 1.48 1.00-2.19 0.96 0.47-1.95
Unknown 1.08 0.66-1.78 0.82 0.33-2.02
Lymphoma‡ 1.02 0.81-1.28 0.74 0.48-1.12
Other Leukemia‡ 0.93 0.72-1.22 1.30 0.82-2.05
Other Malignancy‡ 1.00 0.73-1.37 1.07 0.62-1.84
Nonmalignancy‡ 1.13 0.84-1.53 0.97 0.61-1.54
SAA‡ 1.14 0.86-1.51 0.89 0.57-1.39
Year of transplant
2004/2005 (ref) 1.00 — <.0001 1.00 — <.0001
2002/2003 1.28 1.14-1.44 1.73 1.40-2.15
2000/2001 2.47 2.18-2.79 2.69 2.20-3.30
Search time to HCT (days)
0-60 (ref) 1.00 — <.0001 1.00 — <.0001
61-120 1.29 1.06-1.57 1.83 1.23-2.73
121-180 1.87 1.51-2.31 2.07 1.36-3.14
181+ 2.41 1.94-2.99 2.61 1.72-3.96
Transplant Center volume
(per year)
High (26+) (ref) 1.00 — .0085 1.00 — .06
Medium (10-25) 1.14 1.01-1.29 1.11 0.90-1.37
Low (<10) 1.20 1.07-1.36 1.28 1.04-1.57
Transplant center location
Domestic (ref) 1.00 — <.0001 1.00 — .61
International 2.06 1.63-2.62 0.92 0.68-1.26
AML indicates acute myelogenous leukemia; ALL, acute lymphoblastic leukemia; CML, chronic myelogenous leukemia; MDS, myelodysplastic syndrome;
SAA, severe aplastic anemia; HCT, hematopoietic cell transplantation.
Italic type indicates OR and 95% CI statistically different than reference group.
*Separate adjusted regressions comparing well-matched versus partial or mismatched and comparing partial versus mismatched transplants.
†Reference group for each diagnostic category.
‡Reference group early stage AML.
1338 Biol Blood Marrow Transplant 14:1334-1340, 2008J. Dehn et al.Because international transplants might be associ-
ated with greater ethnic and thus HLA disparity, we
performed a subset analysis (n 5 7049) excluding the
5.5% of patients from international transplant centers.
These results were similar to the full cohort analysis
(data not shown).DISCUSSION
This analysis demonstrates that both donorfileHLA
diversity as well as search and donor selection practices
have greatly improved from 2000 to 2005 with 44% of
transplants being well-matched in 2000/2001 compared
Biol Blood Marrow Transplant 14:1334-1340, 2008 1339Unrelated Donor Hematopoietic Cell Transplantationto 66% in 2004/2005. The NMDP required transplant
centers to type patient/donor pairs at high-resolution
HLA-A, -B, -C, and -DRB1 starting in June 2005
(near the study end). The practice of HLA typing at
the allele level including the HLA-C locus was already
increasing at many centers. This new NMDP require-
ment may have assisted other centers to identify which
donor options might be the best donor match. Some of
the early year transplant pairs may have been considered
amatch based on standardHLA typing technology prior
to transplant, then upon subsequent high-resolution
testing were found to contain mismatches. This trend
to better HLAmatching is a success reflecting advances
in the donor file diversity, improvement in typing tech-
nology, implementation of evidence-based recommen-
dations, and donor selection strategy [13].
Other factors have influenced the availability and
selection of better matched donors. Greater transplant
center experience and volume may improve a patient’s
chances of transplanting with a well-matched donor.
Small volume transplant centers have 20% greater
likelihood of proceeding to transplant with a less-
matched donor compared to high volume centers and
are 28%more likely to choose amismatched than a par-
tially matched donor. Improvements in HLA search
strategy, early initiation of a search, and other factors
may increase the chances of HCT with a better
matched donor, even in less-experienced centers. Im-
munogenetic consultation may be of particular impor-
tance in these less-experienced transplant centers.
Patients with early-stage leukemia had transplants
with a mismatched donor less often than those with in-
termediate and late stage disease. This association
could reflect either more urgent, late-stage transplants
with insufficient time to identify better matched
donors, or alternatively, no better donor identified
during early-stage and disease progression resulting
in the transplant performed with 2 adverse factors: ad-
vanced stage and a lesser matched donor [5]. Because
disease stage at transplant is a potentially modifiable
factor based on clinical decisions, earlier searching
with selection of the best matched donor and HCT at
an earlier disease stage might be a preferred decision-
making strategy, if no effective alternatives are available.
Extended duration searches have not been, and
were not in this study, associated with transplantation
using a better matched donor [14]. This emphasizes
the need to balance the patient’s disease status and ur-
gency with donor matching. Longer search times may
not yield better HLA matched donors. Regression
analysis showed that patients transplanted more than
6 months from the initiation of donor searching were
significantly (2.4 times) more likely to use a less-
matched donor than those transplanted promptly
(within 60 days of searching).
Transplant using a mismatch donor was less com-
mon for older patients. This may reflect deliberatephysician decisions to avoid the added mismatch-asso-
ciated morbidity and mortality in already higher risk,
older recipients. The recent increase in transplants
for older patients using reduced intensity conditioning
(RIC) regimens are designed for better treatment
tolerance. These RIC transplants were more often
performed using more stringent HLA-matching,
perhaps defined by prespecified protocol.
Patients from non-Caucasian racial groups were
more often transplanted with lesser matched donors.
In this study, we evaluated only patients proceeding
to transplant and did not address the recognized racial
disparity in the likelihood of finding a suitable donor.
Increased recruitment of donors from non-Caucasian
racial and ethnic groups as well as specific decision-
making about URD versus alternate therapies, includ-
ing umbilical cord blood HCT, is needed to further
increase the likelihood of good outcome for patients
potentially eligible for HCT.
International transplant centers were twice as likely
to select a less-matcheddonor.Forpatientswithuncom-
monHLA typing, accessing theNMDP’s diverse donor
pool may have been the best option for the patient, pos-
sibly explaining, at least in part, this observation.
We have studied a unique aspect of donor search-
ing, the association of patient non-HLA factors with
selection of HLA matched stem cell donors. Based
upon an assumption that the donor selected by the
transplant center was the best available donor, we are
encouraged that both availability and use of
well-matched donors increased over the study interval,
particularly for non-Caucasian racial and ethnic sub-
groups. Use of new advances, including the recent
NMDP HapLogicSM match calculation algorithm,
could further improve identification of better HLA
matched donors for searching patients leading to
more successful URD HCT.
These results identify statistically significant evi-
dence of the impact of race, disease/stage, age and
transplant center experience on the selection of HLA
well-matched donors. We suggest that all centers
should utilize current HLA strategy and worldwide re-
sources available to aid in donor selection [14]. Initiat-
ing a patient’s URD search early in the disease process,
especially for patients from non-Caucasian racial and
ethnic groups, will provide the best scenario for mak-
ing informed transplant decisions. Additional focus
on donor recruitment efforts and strategies, perhaps
including umbilical cord blood, can help narrow the
gap for non-Caucasian patient groups at increased
risk of transplants with HLA mismatching.ACKNOWLEDGMENTS
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